Home ›
T-Cell Lymphoma Lymphoma Trials ›
NCT06002659
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
Trial Details
NCT ID NCT06002659
Phase PHASE1 / PHASE2
Sponsor Uppsala University
Status RECRUITING
Cancer Type T-Cell Lymphoma Lymphoma
Interventions CAR20(NAP)-T Cyclophosphamide Fludarabine
Locations (sample) Stockholm, Sweden|59.32938,18.06871 Uppsala, Sweden|59.85882,17.63889
Key Eligibility Criteria
Signed informed consent. Relapsed or refractory CD20+ large B-cell lymphoma (DLBCL, NOS or high-grade malignant B-cell lymphoma), mantle cell lymphoma or indolent lymphoma. The patient should have been treated with at least one line of therapy and have no curative treatment option, assessed by the Investigator and docu… Relapsed or refractory CD20+ B-cell lymphoma that are not suitable to receive clinically approved CD19-directed CAR T cell treatment
For full eligibility, visit ClinicalTrials.gov .